Diabetic Cardiomyopathy

NCT04593173 | Unknown

• 1 other identifier: 7905
• Study Type: observational
• Target: 77
• Locations: 1 country
• Sites: 1

Brief Summary

Diabetes represents one of the 10 leading causes of death in the world and concerns 5% of the French population (\> 3.3 million patients). About 30% of diabetic patients will develop heart failure. The specific and early identification of diabetic cardiomyopathy at a subclinical stage (asymptomatic patients with normal LVEF) will thus make it possible to predict the risk of the onset of heart failure and to strengthen their monitoring and further adapt their treatment.

Conditions

Diabetic Cardiomyopathies

Keywords

Diabetes; Cardiomyopathy; Diabetic Cardiomyopathies; Type 2 diabetes; Echocardiography; Left ventricle; strain 2D and 3D

Outcome Measures

Primary Outcomes (1)

• Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients

  The files analysed retrospectily from April 15, 2015 to April 30, 2019 will be examined]

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Type 2 diabetic and hypertensive patients, treated in the Internal Medicine and Diabetology Services of Strasbourg University Hospitals, between 04/15/2015 to 04/30/2019.

You may qualify if:

• Adult patient (≥18 years old)
• Type 2 diabetic and hypertensive subjects, cardiac asymptomatic, without myocardial ischemia documented by Dobutamine stress ultrasound (ESD), having at least 1 additional CV risk factor among: dyslipidemia, active or stopped smoking for less than 3 years, family history (1st degree relationship) of major CV accident before age 60, obliterating arteriopathy of the lower limbs and / or carotid atheroma, or proteinuria.
• Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

You may not qualify if:

• Patient who expressed his opposition to participating in the study
• Valvular heart disease (moderate to severe valve disease), hypertrophic or dilated (MVGi\> 95 g / m2 in women and MVGi\> 115 g / m2 in men), chronic pulmonary;
• History of cardiotoxic chemotherapy;
• Subject under legal protection, under guardianship or under guardianship.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Physiologie et d'Explorations Fonctionnelles

Strasbourg, Starsbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Diabetic Cardiomyopathies; Diabetes Mellitus; Cardiomyopathies; Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Diabetes Complications; Endocrine System Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Central Study Contacts

Samy TALHA, MD

CONTACT

33 3 69 55 13 68; samy.talha@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90; said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2020
• First Posted: October 19, 2020
• Study Start: October 1, 2020
• Primary Completion: September 1, 2021
• Study Completion: November 1, 2021
• Last Updated: October 12, 2021

Record last verified: 2020-10

Locations

FR (1)